retinopathy affects ~1/3 of all people with diabetes(1)
Treatment is in
place and
available, if we
could screen more
efficiently
THERE IS A
SOLUTION…
1) Source: International Diabetes Atlas. IDF Atlas, Eight Edition (2017). Company information.
Need for portable solutions
156 million diabetics
expected to live in rural
156m
areas by 20451
425m
1) Source: IDF Diabetes Atlas 8th Edition
Transition from traditional desktop cameras to AI integrated handheld cameras has started
Traditional equipment
Optomed's handheld
…together with AI
camera…
Low screening coverage
Possibility to increase
Possibility for increased
Capacity constraints
Screening coverage
Volume capabilities
Optomed at a Glance
Attachments
Original document
Permalink
Disclaimer
Optomed Oyj published this content on 26 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 18:11:01 UTC.
Optomed Oyj is a Finland-based medical technology company and a producer of handheld fundus cameras globally. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.